Shots:                                                                                                                                                                

• The P-III study involves assessing of JZP-258 vs PBO in 201 patients in ratio (1:1) with narcolepsy prior treated with sodium oxybate and naïve to sodium oxybate with/out anti-cataplectic treatments
• The P-III study resulted in meeting its 1EPs & 2EPs i.e- reduction in the weekly number of cataplexy attacks and Epworth Sleepiness Scale (ESS) score respectively
• JZP-258 is a novel oxybate product candidate with a unique composition of cations resulting in 92% less sodium than Xyrem (sodium oxybate)- currently being evaluated to treat cataplexy and excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Jazz Pharmaceutical